+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Advanced glycation end products (AGEs) and diabetic vascular complications



Advanced glycation end products (AGEs) and diabetic vascular complications



Current Diabetes Reviews 1(1): 93-106



Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the development and progression of diabetic micro- and macroangiopathy. Among various metabolic derangements implicated in the pathogenesis of diabetic vascular complication, advanced glycation end product (AGE) hypothesis is most compatible with the theory of 'hyperglycemic memory'. In this review, we discuss the molecular mechanisms of diabetic vascular complication, specially focusing on AGEs and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in this devastating disorder are also discussed here.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 051394795

Download citation: RISBibTeXText

PMID: 18220586


Related references

Advanced Glycation End Products (Ages) and Diabetic Vascular Complications. Current Diabetes Reviews 1(1): 93-106, 2005

The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications. Arquivos Brasileiros de Endocrinologia E Metabologia 52(6): 940-950, 2008

Food-advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway. Chinese Journal of Natural Medicines 14(11): 844-855, 2017

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology 14: 2, 2016

Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proceedings of the National Academy of Sciences of the United States of America 91(16): 7742-7746, 1994

Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica et Biophysica Acta 1820(5): 663-671, 2012

Advanced glycation end-products and the progress of diabetic vascular complications. Physiological Research 53(2): 131-142, 2004

The Role of Advanced Glycation End Products in Diabetic Vascular Complications. Diabetes and Metabolism Journal 42(3): 188-195, 2018

Basic and Clinical Research Against Advanced Glycation End Products (Ages): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications. Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery) 10(1): 10-33, 2016

Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications. Recent Advances in Cardiovascular Drug Discovery 10(1): 10-33, 2016

Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications. Journal of Diabetes Investigation 3(2): 107-114, 2012

Receptor for advanced glycation end-products-mediated inflammation and diabetic vascular complications. Journal of Diabetes Investigation 2(3): 155-157, 2011

Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients. Biomed Research International 2017: 7989180, 2018

Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Therapeutic Apheresis and Dialysis 13(6): 534-539, 2010

W13-P-026 The potential role of advanced glycation end products (Ages) in vascular smooth muscle cell proliferation and restenosis in diabetic vasculopathy. Atherosclerosis Suppl.s 6(1): 91-92, 2005